Nottingham, UK – 21st April 2004 – Scancell Ltd, the pioneering Nottingham-based therapeutics company that is harnessing the power of the immune system to fight cancer, has announced the appointment of Dr Michael Capaldi as Chief Executive Officer. Dr Capaldi brings to Scancell extensive commercial and management experience in the pharmaceutical and life sciences industries, together with a strong scientific background.
Commenting on his new position, Dr Capaldi said:
“Scancell is at an exciting stage of development and I look forward to contributing to the future success of the Company. I am convinced that Scancell can make a major contribution towards developing new cancer therapies that harness the power of the immune system.”
Dr Capaldi was previously CEO of Synaptica Ltd where he served from 2000. He has a broad working knowledge of the biopharmaceutical industry with a strong commercial bias, combined with a solid understanding of pharmaceutical discovery and development. He has first hand experience of raising capital from private and public markets to fund early stage biotechnology companies including an IPO of Core Group as a full listing on the London Stock Exchange (LSE) in 1997. He has over 20 years experience in the pharmaceutical and life sciences industry within the UK, Europe and the USA, including over 17 years commercial and general management experience gained with SmithKline Beecham plc, Amersham plc, Core Group plc, Oxford Asymmetry plc and Synaptica Ltd. Prior to this he gained five years multidisciplinary research experience in academic and applied pharmaceutical research and management with Ciba-Geigy.
Michael holds a PhD in Medical Biophysics from the University of Manchester, and has experience of both academic and applied pharmaceutical research. Welcoming Dr Capaldi to the Company, Chairman Nigel Evans said:
“Michael brings significant management, commercial and fund raising experience to Scancell, which will be invaluable as the Company commercialises its therapeutic antibodies and it’s ImmunoBody® technology. Monoclonal antibody technology promises considerable hope for the treatment and prevention of cancer.”
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Thu, 09 Aug 2018 10:48:00
The company first teamed up with Sweden's world-leading medical research university two years ago
Thu, 09 Aug 2018 08:15:00
It has exercised an option on TriGrid, which was developed by Ichor Medical Systems
Wed, 18 Jul 2018 06:09:00